Abstract
Oral helminthic mebendazole (MBZ) has been reported to cause liver injury with inflammatory responses. However, the underlying mechanism remains unknown. To examine the inflammatory reactions, we investigated whether MBZ and other helminthic drugs increase the release of pro-inflammatory cytokines and chemokines using human monocytic cells. The release of interleukin (IL)-8 and tumor necrosis factor (TNF) α from human monocytic THP-1 cells was significantly increased by treatment with MBZ, albendazole (ABZ), fenbendazole (FBZ), or oxibendazole (OBZ), but not by albendazole sulfoxide or praziquantel, suggesting that MBZ and structurally similar drugs can stimulate monocytes and increase the release of pro-inflammatory cytokines. MBZ also significantly increased the phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 and c-Jun N-terminal kinase (JNK) 1/2 in THP-1 cells. Pretreatment with the MAP kinase/ERK kinase 1/2 inhibitor U0126 significantly suppressed the increase of IL-8 and TNFα levels by MBZ, ABZ, FBZ, or OBZ treatment in THP-1 cells, but the p38 mitogen-activated protein kinase inhibitor SB203580 or JNK1/2 inhibitor SP600125 did not. These results suggested that an ERK1/2 pathway plays an important role in the release of IL-8 and TNFα in THP-1 cells treated with MBZ and structurally similar drugs. In conclusion, the release of inflammatory mediators by MBZ might be one of the mechanisms underlying immune-mediated liver injury. This in vitro method may be useful to predict adverse inflammatory reactions that lead to hepatotoxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ammann RW, Eckert J (1996) Cestodes. Echinococcus. Gastroenterol Clin North Am 25:655–689
Baggiolini M, Dewald B, Moser B (1994) Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 55:97–179
Bagheri H, Simiand E, Montastruc JL, Magnaval JF (2004) Adverse drug reactions to anthelmintics. Ann Pharmacother 38:383–388
Bekhti A, Pirotte J (1987) Hepatotoxicity of mebendazole, Relationship with serum concentrations of the drug. Gastroenterol Clin Biol 11:701–703
Bradham CA, Plümpe J, Manns MP, Brenner DA, Trautwein C (1998) Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol 275:G387–G392
Chen K-T, Twu S-J, Chen H-J, Lin R-S (2003) Outbreak of Steravens-Johnson syndrome/toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan. Am J Public Health 93:489–492
Choi GY, Yang HW, Cho SH, Kang DW, Go H, Lee WC, Lee YJ, Jung SH, Kim AN, Cha SW (2008) Acute drug-induced hepatitis caused by albendazole. J Korean Med Sci 23:903–905. doi:10.3346/jkms.2008.23.5.903
Colle I, Naegels S, Hoorens A, Hautekeete M (1999) Granulomatous hepatitis due to mebendazole. J Clin Gastroenterol 28:44–45
Corti N, Heck A, Rentsch K, Zingg W, Jetter A, Stieger B, Pauli-Magnus C (2009) Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers. Eur J Clin Pharmacol 65:999–1006
DeFranco AL, Crowley MT, Finn A, Hambleton J, Weinstein SL (1998) The role of tyrosine kinases and map kinases in LPS-induced signaling. Prog Clin Biol Res 397:119–136
Deng X, Luyendyk JP, Ganey PE, Roth RA (2009) Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev 61:262–282. doi:10.1124/pr.109.001727
Edling Y, Sivertsson L, Andersson TB, Porsmyr-Palmertz M, Ingelman-Sundberg M (2008) Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model. Toxicol In Vitro 22:1588–1594. doi:10.1016/j.tiv.2008.06.011
Edling Y, Sivertsson LK, Butura A, Ingelman-Sundberg M, Ek M (2009) Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro 23:1387–1395. doi:10.1016/j.tiv.2009.07.026
English JM, Cobb MH (2002) Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23:40–45
Ganey PE, Luyendyk JP, Maddox JF, Roth RA (2004) Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 150:35–51. doi:10.1016/j.cbi.2004.09.002
Gottschall DW, Theodorides VJ, Wang R (1990) The metabolism of benzimidazole anthelmintics. Parasitol Today 6:115–124
Guha M, Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13:85–94
Hirosawa M, Nakahara M, Otosaka R, Imoto A, Okazaki T, Takahashi S (2009) The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells. Leuk Res 33:693–699. doi:10.1016/j.leukres.2008.09.028
Holt MP, Ju C (2006) Mechanisms of drug-induced liver injury. AAPS J 8:E48–E54. doi:10.1208/aapsj080106
Ishii Y, Sakai S, Honma Y (2001) Pyridinyl imidazole inhibitor SB203580 activates p44/42 mitogen-activated protein kinase and induces the differentiation of human myeloid leukemia cells. Leuk Res 25:813–820
Jaeschke H (2005) Role of inflammation in the mechanism of acetaminophen-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 1:389–397. doi:10.1517/17425255.1.3.389
Junge U, Mohr W (1983) Mebendazole-hepatitis. Z Gastroenterol 21:736–738
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685
Leonard EJ, Yoshimura T, Tanaka S, Raffeld M (1991) Neutrophil recruitment by intradermally injected neutrophil attractant/activation protein-1. J Invest Dermatol 96:690–694
Numazawa S, Watabe M, Nishimura S, Kurosawa M, Izuno M, Yoshida T (2003) Regulation of ERK-mediated signal transduction by p38 MAP kinase in human monocytic THP-1 cells. J Biochem 133:599–605
O’Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR, Gao B, Kaludercic N, Angeline A, Bernardi P, Brain P, Hougham C (2006) High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 80:580–604
Payne DM, Rossomando AJ, Martino P, Erickson AK, Her JH, Shabanowitz J, Hunt DF, Weber MJ, Sturgill TW (1991) Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J 10:885–892
Roth RA, Luyendyk JP, Maddox JF, Ganey PE (2003) Inflammation and drug idiosyncrasy-is there a connection? J Pharmacol Exp Ther 307:1–8. doi:10.1124/jpet.102.041624
Seitz R, Schwerk W, Arnold R (1983) Hepatocellular drug reactions caused by mebendazole therapy in cystic echinococcosis. Z Gastroenterol 21:324–329
Tafazoli S, Spehar DD, O’Brien PJ (2005) Oxidative stress mediated idiosyncratic drug toxicity. Drug Metab Rev 37:311–325. doi:10.1081/DMR-55227
Acknowledgments
We thank Mr. Brent Bell for reviewing the manuscript. This work was supported by Health and Labor Sciences Research Grants from the Ministry of Health, Labor, and Welfare of Japan (H20-BIO-G001).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mizuno, K., Toyoda, Y., Fukami, T. et al. Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway. Arch Toxicol 85, 199–207 (2011). https://doi.org/10.1007/s00204-010-0584-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-010-0584-y